ArticleTranslational oncology2026
MZB1 marks a B-cell-associated stromal-immune microenvironment in cervical squamous cell carcinoma: a multi-omics analysis.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical squamous cell carcinoma (CSCC) is a common gynecologic malignancy with a heterogeneous tumor immune microenvironment (TIME). The role of MZB1, a B-cell-specific molecular chaperone, in CSCC remains poorly characterized.
methodsWe performed an integrative multi-omics analysis combining spatial proteomics, single-cell RNA sequencing, spatial transcriptomics and bulk transcriptomics to characterize MZB1 expression and its association with the TIME and patient prognosis. All spatial transcriptomics analyses were restricted to malignant regions.
resultsSpatial proteomics revealed MZB1 enrichment in immune-rich regions. Single-cell analysis confirmed predominant MZB1 expression in B cells. Within malignant regions, MZB1-high spots showed significantly higher abundance of B cells (p = 5.04 × 10⁻²⁴), macrophages (p = 2.21 × 10⁻³²), dendritic cells (p = 2.83 × 10⁻²²), CD8+ T cells (p = 1.98 × 10⁻³), and CD4+ T cells (p = 1.24 × 10⁻³). In the TCGA cohort, MZB1 was upregulated in tumors and independently associated with favorable overall survival (HR = 0.894, p = 0.045). Differential expression analysis revealed that MZB1-high spots were characterized by ECM remodeling, BMP signaling, and complement activation (49 upregulated genes). Notably, MZB1-high tumors showed higher T-cell dysfunction/exclusion scores, indicating paradoxical immune evasion despite an immune-infiltrated phenotype.
conclusionsThis integrative analysis suggests MZB1 as a B-cell-specific marker of a stromal-immune microenvironment in CSCC. MZB1-high tumors are characterized by immune infiltration, ECM remodeling, immune checkpoint upregulation, and favorable prognosis. These hypothesis-generating findings suggest that MZB1 may serve as a candidate biomarker for identifying stromal-immune tumors in CSCC, warranting prospective clinical validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.